Cash and cash equivalents, short term deposits, restricted cash and marketable debt securities totaled approximately $19.2M as of September 30, 2025, compared to approximately $15.4M at December 31, 2024.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLMD:
- Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine
- Galmed Pharmaceuticals Reports Promising Results from Aramchol Meglumine Study
- Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study
- Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers
- Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting